DMK Pharmaceuticals (DMK Pharmaceuticals) Cash-to-Debt : 105.78 (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. DMK Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2023 was 105.78.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, DMK Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for DMK Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

DMKPQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 4.88 Max: No Debt
Current: 105.78

During the past 13 years, DMK Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.05. And the median was 4.88.

DMKPQ's Cash-to-Debt is ranked better than
88.54% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs DMKPQ: 105.78

DMK Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for DMK Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

DMK Pharmaceuticals Cash-to-Debt Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

7.46

2.16

1.60

33.51

3.15

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															5.60	3.15	12.40	4.08	105.78

Competitive Comparison of DMK Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Cash-to-Debt falls into.

DMK Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

DMK Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.081	/	(0.343	+	0)
	=	3.15

DMK Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.664	/	(0.063	+	0)
	=	105.78

DMK Pharmaceuticals (OTCPK:DMKPQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

DMK Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0A4X:UK

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Executives

Dorbin John W. Jr.	officer: General Counsel	C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen	officer: CFO	C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi	director, officer: CEO	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi	director	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio	director	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd	director, 10 percent owner, officer: President/CEO	PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss	officer: Chief Medical Officer	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto	officer: Chief Financial Officer	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai	director	1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins	officer: Chief Financial Officer	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels	officer: Vice President of Operations	11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf	director	C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams	director	26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134